Filter
528
Filtered Results: 528
Text search:
BioNTech
Featured
Recommendations
65
New Publications
76
Language
Document type
No document type
157
Studies & Reports
126
Guidelines
108
Fact sheets
56
Manuals
38
Strategic & Response Plan
16
Training Material
7
Infographics
6
Resource Platforms
5
Situation Updates
4
Online Courses
3
Brochures
1
Videos
1
Countries / Regions
India
43
Global
20
Germany
19
Brazil
13
South Africa
11
Russia
11
Nepal
10
Ukraine
10
Latin America and the Carribbean
9
Argentina
9
Mozambique
8
Middle East and North Africa
7
Rwanda
5
Africa
5
Bangladesh
5
Nigeria
4
Tanzania
4
West and Central Africa
4
Western and Central Europe
4
Paraguay
4
Zambia
4
Colombia
3
Kenya
3
China
3
Chile
3
Cameroon
3
South–East Asia Region
3
East and Southern Africa
3
Ethiopia
3
Ecuador
3
Myanmar / Burma
3
Thailand
2
Syria
2
Peru
2
Malawi
2
Zimbabwe
2
Philippines
2
USA
2
Asia
2
Spain
2
Vietnam
2
Uganda
2
Namibia
2
Angola
2
Botswana
2
South Sudan
2
El Salvador
1
Turkey
1
Ghana
1
Benin
1
Sierra Leone
1
Kazakhstan
1
Iran
1
Senegal
1
Afghanistan
1
Guinea
1
Haiti
1
Cambodia
1
Guinea-Bissau
1
Congo, Democratic Republic of
1
Eastern Europe and Central Asia
1
France
1
United Kingdom
1
Portugal
1
Belarus
1
Papua New Guinea
1
Sudan
1
Yemen
1
Central African Republic
1
Libya
1
Iraq
1
Somalia
1
Liberia
1
Madagascar
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
200
Clinical Guidelines
33
Pharmacy & Technologies
21
Key Resources
20
Women & Child Health
8
Public Health
6
Capacity Building
1
Annual Report MEDBOX
1
Toolboxes
COVID-19
179
AMR
32
NTDs
27
Rapid Response
23
TB
23
Planetary Health
22
HIV
18
Pharmacy
17
Refugee
16
Ebola & Marburg
12
Health Financing Toolbox
8
Global Health Education
7
Social Ethics
6
Caregiver
6
Mental Health
5
Cholera
5
Conflict
5
NCDs
4
Specific Hazards
3
Disability
2
Malaria
1
Zika
1
Polio
1
Information about vaccine administration
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) h...
The guidelines reiterate that the general principles of ethics for biomedical research involving human participants shall also be applicable. In addition, the guidelines specify unique provisions for stem cells, because of their inherent property for unlimited proliferation, differentiation to cells...
These guidelines have been developed for scientific purpose with the main aim to guide the regulatory authority for evaluating probiotic products in our country.
With the growing prevalence of type 2 diabetes, particularly in emerging countries, its management in the context of available resources should be considered. International guidelines, while comprehensive and scientifically valid, may not be appropriate for regions such as Asia, Latin America or Afr...
Original Research
African Journal of Primary Health Care & Family Medicine
ISSN: (Online) 2071-2936, (Print) 2071-2928
Open Access
Early data from US biotech Moderna has revealed that its Covid-19 vaccine candidate is 94.5 per cent effective, raising hopes that a range of immunisations will be available to help end the pandemic.
The interim analysis of the vaccine, currently known as mRNA-1273, comes after 95 trial particip...
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna);
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. ...
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer...
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Seit August 2021 empfiehlt die Ständige Impfkommission (STIKO) allen Kindern und Jugendlichen ab 12 Jahren die Corona-Schutzimpfung mit Comirnaty® von BioNTech/Pfizer. Seit Mitte Dezember können auch Kinder zwischen 5 und 11 Jahren mit dem darauf angepassten Impfstoff von BioNTech/Pfizer geimpft ...
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
En Paraguay, la vacunación contra COVID-19 inició el 22 de febrero de 2021. Se han autorizado un total de siete vacunas: Bharat-Covaxin, Moderna, Pfizer-BioNTech, AstraZeneca, Sinopharm, Sputnik V- Gamaleya y CoronaVac-Sinovac. Los grupos prioritarios de vacunación están definidos según el Plan...
The Schistosomiasis Resource Center at the Biomedical Research Institute is a unique schistosomiasis research supply laboratory funded by the NIAID (NIAID-NIH)
The SRC provides Schistosoma life cycle reagents free of charge to scientists, students, biotech and independent investigators in the U.S...
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi...
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...
